1-3 of 3
Elizabeth O. Stenger
Close
Sort by
Journal Articles

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT

Ashley V. Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, James A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S. Kean, K. Scott Baker, Lauri M. Burroughs, Jeffrey R. Andolina, Shalini Shenoy, Philip Roehrs, Rabi Hanna, Julie-An Talano, Kirk R. Schultz, Elizabeth O. Stenger, Howard Lin, Adi Zoref-Lorenz, Kenneth L. McClain, Michael B. Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3725–3734.
https://doi.org/10.1182/bloodadvances.2022009478
Published: 2023
Includes: Supplemental data
Journal Articles

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure

Clinical Trials & Observations
Elizabeth O. Stenger, Benjamin Watkins, Kelsey Rogowski, Kuang-Yueh Chiang, Ann Haight, Kathryn Leung, Muna Qayed, Sharmila Raghunandan, Yvonne Suessmuth, Leslie Kean, John Horan
Journal: Blood Advances
Blood Adv (2023) 7 (10): 2196–2205.
https://doi.org/10.1182/bloodadvances.2022008545
Published: 2023
Includes: Supplemental data
Journal Articles

Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders

Clinical Trials & Observations
Mark T. Vander Lugt, Xiaohua Chen, Maria L. Escolar, Beth A. Carella, Jessie L. Barnum, Randy M. Windreich, Memphis J. Hill, Michelle Poe, Rebecca A. Marsh, Heather Stanczak, Elizabeth O. Stenger, Paul Szabolcs
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3041–3052.
https://doi.org/10.1182/bloodadvances.2020001940
Published: 2020
Includes: Supplemental data